{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:45:12Z","timestamp":1773755112009,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1038\/tpj.2014.7","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T11:01:44Z","timestamp":1393930904000},"page":"328-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"A","family":"Di Paolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Polillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Capecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Cervetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Fontanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Arici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ciabatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Hrelia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"BFtpj20147_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","volume":"22","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S, European Leukemia N . Response definitions and European leukemianet management recommendations. Best Pract Res Clin Haematol 2009; 22: 331\u2013341.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFtpj20147_CR2","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496\u20133499.","journal-title":"Blood"},{"key":"BFtpj20147_CR3","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","volume":"101","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K et al. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 2010; 101: 2186\u20132192.","journal-title":"Cancer Sci"},{"key":"BFtpj20147_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/clpt.2010.186","volume":"88","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Wakita H, Miura M, Scott SA, Nishii K, Masuko M et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther 2010; 88: 809\u2013813.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj20147_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/hon.2005","volume":"30","author":"M Koren-Michowitz","year":"2012","unstructured":"Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 2012; 30: 200\u2013205.","journal-title":"Hematol Oncol"},{"key":"BFtpj20147_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00277-011-1394-x","volume":"91","author":"E Faber","year":"2012","unstructured":"Faber E, Friedecky D, Micova K, Rozmanova S, Divoka M, Jarosova M et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol 2012; 91: 923\u2013929.","journal-title":"Ann Hematol"},{"key":"BFtpj20147_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","volume":"35","author":"M Maffioli","year":"2011","unstructured":"Maffioli M, Camos M, Gaya A, Hernandez-Boluda JC, Alvarez-Larran A, Domingo A et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 2011; 35: 1014\u20131019.","journal-title":"Leuk Res"},{"key":"BFtpj20147_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/annonc\/mds532","volume":"24","author":"SJ Seong","year":"2013","unstructured":"Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 2013; 24: 756\u2013760.","journal-title":"Ann Oncol"},{"key":"BFtpj20147_CR9","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739\u20133745.","journal-title":"Blood"},{"key":"BFtpj20147_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL . Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010; 24: 765\u2013770.","journal-title":"Leukemia"},{"key":"BFtpj20147_CR11","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 4750\u20134758.","journal-title":"Clin Cancer Res"},{"key":"BFtpj20147_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98: 193\u2013200.","journal-title":"Haematologica"},{"key":"BFtpj20147_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2013; 121: 628\u2013637.","journal-title":"Blood"},{"key":"BFtpj20147_CR14","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1128\/MCB.21.16.5471-5477.2001","volume":"21","author":"JW Jonker","year":"2001","unstructured":"Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 2001; 21: 5471\u20135477.","journal-title":"Mol Cell Biol"},{"key":"BFtpj20147_CR15","doi-asserted-by":"publisher","first-page":"7902","DOI":"10.1128\/MCB.23.21.7902-7908.2003","volume":"23","author":"JW Jonker","year":"2003","unstructured":"Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH . Deficiency in the organic cation transporters 1 and 2 (Oct1\/Oct2 [Slc22a1\/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003; 23: 7902\u20137908.","journal-title":"Mol Cell Biol"},{"key":"BFtpj20147_CR16","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381\u20132388.","journal-title":"J Clin Oncol"},{"key":"BFtpj20147_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D . Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012; 87: 687\u2013691.","journal-title":"Am J Hematol"},{"key":"BFtpj20147_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1023\/A:1020909324909","volume":"29","author":"SL Beal","year":"2002","unstructured":"Beal SL . Commentary on significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2002; 29: 403\u2013410.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"BFtpj20147_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO . Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFtpj20147_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN . Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFtpj20147_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143\u2013151.","journal-title":"AAPS J"},{"key":"BFtpj20147_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO . Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558\u2013569.","journal-title":"AAPS J"},{"issue":"Suppl 4","key":"BFtpj20147_CR23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","volume":"20","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Dreyling M, Group EGW. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 105\u2013107.","journal-title":"Ann Oncol"},{"key":"BFtpj20147_CR24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), National Cancer Institute, NIH, Version 4.02 2009."},{"key":"BFtpj20147_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1755-0998.2010.02847.x","volume":"10","author":"L Excoffier","year":"2010","unstructured":"Excoffier L, Lischer HE . Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 2010; 10: 564\u2013567.","journal-title":"Mol Ecol Resour"},{"key":"BFtpj20147_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1470-2045(10)70258-8","volume":"12","author":"T Buclin","year":"2011","unstructured":"Buclin T, Widmer N, Biollaz J, Decosterd LA . Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncol 2011; 12: 9\u201311.","journal-title":"Lancet Oncol"},{"key":"BFtpj20147_CR27","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008; 14: 7102\u20137109.","journal-title":"Clin Cancer Res"},{"key":"BFtpj20147_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/jcp.20081","volume":"201","author":"G Ciarimboli","year":"2004","unstructured":"Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol 2004; 201: 420\u2013428.","journal-title":"J Cell Physiol"},{"key":"BFtpj20147_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/372549a0","volume":"372","author":"D Grundemann","year":"1994","unstructured":"Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H . Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549\u2013552.","journal-title":"Nature"},{"key":"BFtpj20147_CR30","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2009.166","volume":"23","author":"A Davies","year":"2009","unstructured":"Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009; 23: 1999\u20132006.","journal-title":"Leukemia"},{"key":"BFtpj20147_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009; 158: 1153\u20131164.","journal-title":"Br J Pharmacol"},{"key":"BFtpj20147_CR32","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012; 18: 5780\u20135787.","journal-title":"Clin Cancer Res"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj20147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj20147","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj20147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:41:07Z","timestamp":1647945667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj20147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["BFtpj20147"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2014.7","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]},"assertion":[{"value":"18 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}